Tom Mikkelsen

Summary

Affiliation: Henry Ford Hospital
Country: USA

Publications

  1. ncbi request reprint The induction of autophagy by gamma-radiation contributes to the radioresistance of glioma stem cells
    Stephanie L Lomonaco
    Department of Neurosurgery, William and Karen Davidson Laboratory of Cell Signaling and Tumorigenesis, Hermelin Brain Tumor Center, Henry Ford Hospital, Detroit, MI 48202, USA
    Int J Cancer 125:717-22. 2009
  2. doi request reprint Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency
    Tom Mikkelsen
    Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Hospital, Detroit, MI 48202, USA
    Int J Cancer 124:2719-27. 2009
  3. doi request reprint Phase I/II dose escalation trial of concurrent temozolomide and whole brain radiation therapy for multiple brain metastasis
    Tom Mikkelsen
    Hermelin Brain Tumor Center, Henry Ford Health System, Detroit, MI 48202, USA
    J Neurooncol 100:241-7. 2010
  4. doi request reprint Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma
    T Mikkelsen
    Hermelin Brain Tumor Center, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI 48202, USA
    J Neurooncol 92:57-63. 2009
  5. pmc Cilengitide induces autophagy-mediated cell death in glioma cells
    Stephanie L Lomonaco
    William and Karen Davidson Laboratory of Cell Signaling and Tumorigenesis, Detroit, MI 48202, USA
    Neuro Oncol 13:857-65. 2011
  6. pmc The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline
    Mario Ammirati
    Department of Neurosurgery, Ohio State University Medical Center, Columbus, OH, USA
    J Neurooncol 96:85-96. 2010
  7. pmc GRP78 is overexpressed in glioblastomas and regulates glioma cell growth and apoptosis
    Hae Kyung Lee
    Department of Neurosurgery and Hermelin Brain Tumor Center, Henry Ford Health System, Detroit, MI 48202, USA
    Neuro Oncol 10:236-43. 2008
  8. pmc Mesenchymal stem cells deliver synthetic microRNA mimics to glioma cells and glioma stem cells and inhibit their cell migration and self-renewal
    Hae Kyung Lee
    Davidson Laboratory of Cell Signaling and Tumorigenesis, Hermelin Brain Tumor Center, Department of Neurosurgery, Henry Ford Hospital, Detroit, MI, USA
    Oncotarget 4:346-61. 2013
  9. pmc Increased chemotactic migration and growth in heparanase-overexpressing human U251n glioma cells
    Xin Hong
    Department of Neurology, Henry Ford Health Science Center, Detroit, MI, USA
    J Exp Clin Cancer Res 27:23. 2008
  10. doi request reprint Tumor vascular leakiness and blood volume estimates in oligodendrogliomas using perfusion CT: an analysis of perfusion parameters helping further characterize genetic subtypes as well as differentiate from astroglial tumors
    Jayant Narang
    Division of Neuroradiology, Department of Radiology, Henry Ford Health System, 2799 West Grand Blvd, Detroit, MI 48202, USA
    J Neurooncol 102:287-93. 2011

Research Grants

  1. INTEGRIN ANTAGONISTS IN GLIOMA BIOLOGY, IMAGING, THERAPY
    Tom Mikkelsen; Fiscal Year: 2003
  2. MOLECULAR GLIOMA THERAPIES AND DIAGNOSTICS
    Tom Mikkelsen; Fiscal Year: 2004
  3. A MULTI-USE GLIOMA BIOREPOSITORY
    Tom Mikkelsen; Fiscal Year: 2006
  4. NEW APPLICATIONS IN BRAIN TUMOR THERAPY
    Tom Mikkelsen; Fiscal Year: 2007

Collaborators

Detail Information

Publications83

  1. ncbi request reprint The induction of autophagy by gamma-radiation contributes to the radioresistance of glioma stem cells
    Stephanie L Lomonaco
    Department of Neurosurgery, William and Karen Davidson Laboratory of Cell Signaling and Tumorigenesis, Hermelin Brain Tumor Center, Henry Ford Hospital, Detroit, MI 48202, USA
    Int J Cancer 125:717-22. 2009
    ..Collectively, these results indicate that the induction of autophagy contributes to the radioresistance of these cells and autophagy inhibitors may be employed to increase the sensitivity of CD133+ GSCs to gamma-radiation...
  2. doi request reprint Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency
    Tom Mikkelsen
    Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Hospital, Detroit, MI 48202, USA
    Int J Cancer 124:2719-27. 2009
    ..Our results demonstrate that blockade of alphav integrins mediates an unanticipated rapid potentiation of radiation, and suggests possible clinical translation for glioma therapy...
  3. doi request reprint Phase I/II dose escalation trial of concurrent temozolomide and whole brain radiation therapy for multiple brain metastasis
    Tom Mikkelsen
    Hermelin Brain Tumor Center, Henry Ford Health System, Detroit, MI 48202, USA
    J Neurooncol 100:241-7. 2010
    ..1 months. The maximum tolerated dose of daily TMZ with concurrent WBRT was 95 mg/m(2). Despite dose escalation, outcomes did not appear to be improved in the sample treated...
  4. doi request reprint Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma
    T Mikkelsen
    Hermelin Brain Tumor Center, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI 48202, USA
    J Neurooncol 92:57-63. 2009
    ..This treatment regimen should be studied as part of a formal randomized clinical trial...
  5. pmc Cilengitide induces autophagy-mediated cell death in glioma cells
    Stephanie L Lomonaco
    William and Karen Davidson Laboratory of Cell Signaling and Tumorigenesis, Detroit, MI 48202, USA
    Neuro Oncol 13:857-65. 2011
    ..We found that cilengitide induced autophagy collectively in glioma cells, xenografts, and GSCs, which contributed to its cytotoxic effects and sensitized these cells to γ-radiation...
  6. pmc The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline
    Mario Ammirati
    Department of Neurosurgery, Ohio State University Medical Center, Columbus, OH, USA
    J Neurooncol 96:85-96. 2010
    ..What evidence is available regarding the use of whole brain radiation therapy (WBRT), stereotactic radiosurgery (SRS), surgical resection or chemotherapy for the treatment of recurrent/progressive brain metastases?..
  7. pmc GRP78 is overexpressed in glioblastomas and regulates glioma cell growth and apoptosis
    Hae Kyung Lee
    Department of Neurosurgery and Hermelin Brain Tumor Center, Henry Ford Health System, Detroit, MI 48202, USA
    Neuro Oncol 10:236-43. 2008
    ..Thus, GRP78 contributes to the increased apoptosis resistance and growth of glioma cells and may provide a target for enhancing the therapeutic responsiveness of these tumors...
  8. pmc Mesenchymal stem cells deliver synthetic microRNA mimics to glioma cells and glioma stem cells and inhibit their cell migration and self-renewal
    Hae Kyung Lee
    Davidson Laboratory of Cell Signaling and Tumorigenesis, Hermelin Brain Tumor Center, Department of Neurosurgery, Henry Ford Hospital, Detroit, MI, USA
    Oncotarget 4:346-61. 2013
    ..These results suggest that MSCs can deliver synthetic exogenous miRNA mimics to glioma cells and GSCs and may provide an efficient route of therapeutic miRNA delivery in vivo...
  9. pmc Increased chemotactic migration and growth in heparanase-overexpressing human U251n glioma cells
    Xin Hong
    Department of Neurology, Henry Ford Health Science Center, Detroit, MI, USA
    J Exp Clin Cancer Res 27:23. 2008
    ..Focal adhesion kinase (FAK) and extracellular signal-regulated kinase 1 (ERK1) signaling were not altered by heparanase-overexpression. These results indicate that heparanase has pleiotropic effects on tumor cells...
  10. doi request reprint Tumor vascular leakiness and blood volume estimates in oligodendrogliomas using perfusion CT: an analysis of perfusion parameters helping further characterize genetic subtypes as well as differentiate from astroglial tumors
    Jayant Narang
    Division of Neuroradiology, Department of Radiology, Henry Ford Health System, 2799 West Grand Blvd, Detroit, MI 48202, USA
    J Neurooncol 102:287-93. 2011
    ..Low grade OGs showed slightly higher CBV as compared to low grade astroglial tumors, whereas higher grade OGs showed significantly lower PS values as compared to higher grade astroglial tumors despite showing high CBV...
  11. doi request reprint Correlation of immunohistologic and perfusion vascular parameters with MR contrast enhancement using image-guided biopsy specimens in gliomas
    Rajan Jain
    Division of Neuroradiology, Department of Radiology, Henry Ford Health System, Detroit, MI 48202, USA
    Acad Radiol 18:955-62. 2011
    ..We also compared perfusion computed tomography (PCT) parameters such as cerebral blood volume (CBV), cerebral blood flow (CBF), and permeability surface area-product (PS) with the presence or absence of contrast enhancement...
  12. pmc The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline
    Mark E Linskey
    Department of Neurosurgery, University of California Irvine Medical Center, Orange, CA, USA
    J Neurooncol 96:45-68. 2010
    ....
  13. pmc Gliosarcoma stem cells undergo glial and mesenchymal differentiation in vivo
    Ana C deCarvalho
    Department of Neurosurgery, Henry Ford Hospital, Detroit, Michigan 48202 2689, USA
    Stem Cells 28:181-90. 2010
    ..The GS experimental tumors phenocopied the parental tumor, exhibiting biphasic glial and mesenchymal components, constituting a clinically relevant model to investigate mesenchymal differentiation in GBMs...
  14. ncbi request reprint Decrease of endogenous vascular endothelial growth factor may not affect glioma cell proliferation and invasion
    Xin Hong
    Department of Neurosurgery, Henry Ford Health Science Center, Detroit, MI 48202, USA
    J Exp Ther Oncol 6:219-29. 2007
    ..Our data indicate that the decrease of endogenous VEGF expression may not affect glioma cell proliferation and invasion...
  15. doi request reprint Can permeability measurements add to blood volume measurements in differentiating tumefactive demyelinating lesions from high grade gliomas using perfusion CT?
    Rajan Jain
    Division of Neuroradiology, Department of Radiology, Henry Ford Health System, 2799 West Grand Blvd, Detroit, MI 48202, USA
    J Neurooncol 97:383-8. 2010
    ....
  16. doi request reprint The role of salvage reirradiation for malignant gliomas that progress on bevacizumab
    Roy G Torcuator
    Hermelin Brain Tumor Center, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI 48202, USA
    J Neurooncol 97:401-7. 2010
    ..2 vs. 3.3 months, P = 0.03) and higher radiographic response rate (22 vs. 0%, P = 0.049). FSRT or SRS followed by bevacizumab + chemotherapy may have a role for patients who progress on bevacizumab...
  17. pmc Insulin-like growth factor binding protein 7 mediates glioma cell growth and migration
    Wei Jiang
    Hermelin Brain Tumor Center, Department of Neurosurgery, Henry Ford Hospital, Detroit, MI 48202, USA
    Neoplasia 10:1335-42. 2008
    ..These two factors together suggest that IGFBP-7 can regulate glioma cell migration through the AKT-ERK pathway, thereby playing an important role in glioma growth and migration...
  18. ncbi request reprint Initial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosis
    Roy Torcuator
    Hermelin Brain Tumor Center, Department of Neurosurgery, Henry Ford Hospital, 2799 W Grand Blvd, Detroit, MI 48202, USA
    J Neurooncol 94:63-8. 2009
    ..We retrospectively reviewed 6 patients with biopsy proven cerebral radiation necrosis treated with bevacizumab between 2006 and 2008...
  19. pmc The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline
    Steven N Kalkanis
    Department of Neurosurgery, Henry Ford Health System, 2799 West Grand Blvd, K 11, Detroit, MI 48202, USA
    J Neurooncol 96:33-43. 2010
    ..There is insufficient evidence to make a recommendation for patients with poor performance scores, advanced systemic disease, or multiple brain metastases...
  20. ncbi request reprint Associations among magnetic resonance spectroscopy, apparent diffusion coefficients, and image-guided histopathology with special attention to radiation necrosis
    Jack P Rock
    Hermelin Brain Tumor Center, Henry Ford Hospital, Detroit, Michigan 48202, USA
    Neurosurgery 54:1111-7; discussion 1117-9. 2004
    ..To improve our clinical ability to discriminate among these histological entities, we have analyzed MRS in conjunction with apparent diffusion coefficient (ADC) sequences derived from magnetic resonance imaging...
  21. pmc The role of prophylactic anticonvulsants in the management of brain metastases: a systematic review and evidence-based clinical practice guideline
    Tom Mikkelsen
    Department of Neurology, Henry Ford Health System, Detroit, MI, USA
    J Neurooncol 96:97-102. 2010
    ..Do prophylactic anticonvulsants decrease the risk of seizure in patients with metastatic brain tumors compared with no treatment?..
  22. doi request reprint Morphologic MRI features, diffusion tensor imaging and radiation dosimetric analysis to differentiate pseudo-progression from early tumor progression
    Ajay Agarwal
    Division of Neuroradiology, Department of Radiology, Henry Ford Health System, 2799 West Grand Blvd, Detroit, MI 48202, USA
    J Neurooncol 112:413-20. 2013
    ..The larger sizes of the T2-FLAIR signal abnormality and the enhancing component of the lesion favor ETP. There was no correlation between the pattern of MRI changes and radiation dose distribution between PsP and ETP groups...
  23. pmc MicroRNA-145 is downregulated in glial tumors and regulates glioma cell migration by targeting connective tissue growth factor
    Hae Kyung Lee
    Davidson Laboratory of Cell Signaling and Tumorigenesis, Hermelin Brain Tumor Center, Department of Neurosurgery, Henry Ford Hospital, Detroit, Michigan, USA
    PLoS ONE 8:e54652. 2013
    ..In addition miR-145 regulates glioma cell migration by targeting CTGF which downregulates SPARC expression. Therefore, miR-145 is an attractive therapeutic target for anti-invasive treatment of astrocytic tumors...
  24. doi request reprint Treatment induced necrosis versus recurrent/progressing brain tumor: going beyond the boundaries of conventional morphologic imaging
    Rajan Jain
    Division of Neuroradiology, Department of Radiology, Henry Ford Hospital, Detroit, MI, USA
    J Neurooncol 100:17-29. 2010
    ..In this review we will discuss various functional neuro-imaging modalities, their advantages and limitations and also their utility in treatment planning...
  25. doi request reprint Imaging response criteria for recurrent gliomas treated with bevacizumab: role of diffusion weighted imaging as an imaging biomarker
    Rajan Jain
    Henry Ford Hospital, Detroit, MI, USA
    J Neurooncol 96:423-31. 2010
    ..These findings suggest that DWI may be used as an additional imaging biomarker for early treatment response...
  26. pmc Differentiating treatment-induced necrosis from recurrent/progressive brain tumor using nonmodel-based semiquantitative indices derived from dynamic contrast-enhanced T1-weighted MR perfusion
    Jayant Narang
    Division of Neuroradiology, Department of Radiology, Henry Ford Health System, Detroit, MI 48202, USA
    Neuro Oncol 13:1037-46. 2011
    ....
  27. doi request reprint Prognostic vascular imaging biomarkers in high-grade gliomas: tumor permeability as an adjunct to blood volume estimates
    Rajan Jain
    Department of Radiology, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI 48202, USA
    Acad Radiol 20:478-85. 2013
    ....
  28. doi request reprint Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma
    Richard M Zuniga
    Henry Ford Health System, Hermelin Brain Tumor Center, 2799 W Grand Blvd, Detroit, MI 48202, USA
    J Neurooncol 99:237-42. 2010
    ..Slow tapering of the bevacizumab dose after tumour progression may prevent this from occurring and improve responsiveness to next-line therapies...
  29. doi request reprint Predicting survival in glioblastomas using diffusion tensor imaging metrics
    Sona Saksena
    Department of Radiology, Henry Ford Health System, Detroit, Michigan 48202, USA
    J Magn Reson Imaging 32:788-95. 2010
    ..To retrospectively correlate various diffusion tensor imaging (DTI) metrics in patients with glioblastoma multiforme (GBM) with patient survival analysis and also degree of tumor proliferation index determined histologically...
  30. pmc Model selection for DCE-T1 studies in glioblastoma
    Hassan Bagher-Ebadian
    Department of Neurology, Henry Ford Hospital, Detroit, Michigan 48202, USA
    Magn Reson Med 68:241-51. 2012
    ..99). We conclude that the three parameters of the standard model are sufficient to fit dynamic contrast enhanced T(1) data in glioblastoma under the conditions of the experiment...
  31. pmc Development of a novel animal model to differentiate radiation necrosis from tumor recurrence
    Sanath Kumar
    Department of Radiation Oncology, Henry Ford Health System, Detroit, MI 48202, USA
    J Neurooncol 108:411-20. 2012
    ..Luxol fast blue and lectin staining showed demyelination and vascular injury in brain tissue consistent with radiation necrosis. We have developed a novel model of radiation necrosis in rats bearing glioma...
  32. pmc Polynuclear platinum anticancer drugs are more potent than cisplatin and induce cell cycle arrest in glioma
    Christine Billecke
    Hermelin Brain Tumor Center and Department of Neurosurgery, Henry Ford Hospital, Detroit, MI 48202, USA
    Neuro Oncol 8:215-26. 2006
    ..Together, these findings support continued development of BBR3610 for clinical use against glioma and provide a framework for future investigation of mechanism of action...
  33. pmc Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers
    Rajan Jain
    Division of Neuroradiology, Department of Radiology, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI 48202, USA
    Radiology 267:212-20. 2013
    ....
  34. pmc Aurora A is differentially expressed in gliomas, is associated with patient survival in glioblastoma and is a potential chemotherapeutic target in gliomas
    Norman L Lehman
    Department of Pathology and Laboratory Medicine, The Hermelin Brain Tumor Center, Henry Ford Hospital, and Department of Pathology, Wayne State University, Detroit, MI, USA
    Cell Cycle 11:489-502. 2012
    ..Thus, in addition to being significantly associated with survival in glioblastoma, Aurora A is a potential new drug target for the treatment of glioblastoma and possibly other glial neoplasms...
  35. ncbi request reprint A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue
    Milena Cankovic
    Department of Pathology, Henry Ford Hospital, Detroit, MI 48202, USA
    Lab Invest 87:392-7. 2007
    ..The objective of this study was to develop a reliable, clinically validated assay for detection of epigenetic silencing of the MGMT gene using formalin-fixed, paraffin-embedded brain tumor resections and methylation-specific PCR...
  36. pmc The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline
    Timothy C Ryken
    Department of Neurosurgery, Iowa Spine and Brain Institute, Iowa City, IA, USA
    J Neurooncol 96:103-14. 2010
    ..2) comparison of different doses of steroid therapy...
  37. ncbi request reprint Cloning and characterization of human RTVP-1b, a novel splice variant of RTVP-1 in glioma cells
    Cunli Xiang
    Hermelin Brain Tumor Center, Department of Neurosurgery, Henry Ford Health System, Detroit, MI 48202, USA
    Biochem Biophys Res Commun 362:612-8. 2007
    ..Overexpression of RTVP-1b increased glioma cell proliferation but did not affect cell migration. Our results suggest that RTVP-1b represents a potential prognostic marker and therapeutic target in gliomas...
  38. ncbi request reprint First-pass perfusion computed tomography: initial experience in differentiating recurrent brain tumors from radiation effects and radiation necrosis
    Rajan Jain
    Department of Radiology, Division of Neuroradiology, Henry Ford Hospital, Detroit, Michigan 48202, USA
    Neurosurgery 61:778-86; discussion 786-7. 2007
    ..To differentiate recurrent tumors from radiation effects and necrosis in patients with irradiated brain tumors using perfusion computed tomographic (PCT) imaging...
  39. pmc The Corpus Callosum Wallerian Degeneration in the Unilateral Brain Tumors: Evaluation with Diffusion Tensor Imaging (DTI)
    Sona Saksena
    Division of Neuroradiology, Department of Radiology, Henry Ford Health System, Detroit, MI 48202, USA
    J Clin Diagn Res 7:320-5. 2013
    ....
  40. ncbi request reprint Salvage reirradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival
    Mehul Patel
    Henry Ford Health System, Detroit, MI, USA
    J Neurooncol 92:185-91. 2009
    ..To determine the radiographic and clinical efficacy of stereotactic single dose radiosurgery (SRS) and fractionated stereotactic radiotherapy (FSRT) as salvage therapy for glioblastoma (GBM) at recurrence...
  41. pmc FK506 binding protein mediates glioma cell growth and sensitivity to rapamycin treatment by regulating NF-kappaB signaling pathway
    Wei Jiang
    Hermelin Brain Tumor Center, Department of Neurosurgery, Henry Ford Hospital, Detroit, MI 48202, USA
    Neoplasia 10:235-43. 2008
    ..In conclusion, our study demonstrates that FKBP5 plays an important role in glioma growth and chemoresistance through regulating signal transduction of the NF-kappaB pathway...
  42. pmc Subcurative radiation significantly increases cell proliferation, invasion, and migration of primary glioblastoma multiforme in vivo
    Adarsh Shankar
    Department of Radiology, Henry Ford Hospital, Detroit, MI 48202, USA
    Chin J Cancer 33:148-58. 2014
    ..Our study provides insights into possible mechanisms of treatment resistance following radiation therapy for GBM. ..
  43. ncbi request reprint Key determinants of short-term and long-term glioblastoma survival: A 14-year retrospective study of patients from the Hermelin Brain Tumor Center at Henry Ford Hospital
    Paul Mazaris
    Departments of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Health System, 2799 West Grand Boulevard, Detroit 48202, USA
    Clin Neurol Neurosurg 120:103-12. 2014
    ..We retrospectively analyzed the relationship of clinical, epidemiologic, genetic and molecular characteristics with survival in patients with GBM...
  44. pmc Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab
    Michael Prados
    Department of Neurosurgery, University of California San Francisco, 400 Parnassus Ave, A 808, San Francisco, CA 94143, USA
    Neuro Oncol 13:143-51. 2011
    ..Clarifying the relationship of OR and survival is important for determining whether OR can be a reliable predictor of the benefit of a therapeutic agent in patients with recurrent GBM...
  45. pmc Preclinical characterization of signal transducer and activator of transcription 3 small molecule inhibitors for primary and metastatic brain cancer therapy
    Hikmat H Assi
    Department of Neurosurgery and Department of Cell and Developmental Biology, University of Michigan School of Medicine, Ann Arbor, Michigan H H A, C P, N V, J S, R D, P R L, M G C Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California H H A Department of Chemistry, Eastern Michigan University, Ypsilanti, Michigan E P, J D H Department of Pathology, University of Michigan School of Medicine, University Hospital, Ann Arbor, Michigan H A Department of Biomedical and Molecular Sciences, Queen s University School of Medicine, Kingston, Ontario, Canada L R and Department of Neurology, Henry Ford Hospital, Detroit, Michigan T M
    J Pharmacol Exp Ther 349:458-69. 2014
    ..Our data strongly support further development of CPA-7-derived compounds with increased permeability to enhance their efficacy in primary and metastatic brain tumors. ..
  46. ncbi request reprint Glioblastoma cell enrichment is critical for analysis of phosphorylated drug targets and proteomic-genomic correlations
    Claudius Mueller
    Authors Affiliations Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia Departments of Neurosurgery, Henry Ford Hospital, Detroit and Pathology, Henry Ford Hospital, Detroit, Michigan
    Cancer Res 74:818-28. 2014
    ..Our findings highlight the necessity for careful upfront cellular enrichment in biospecimens that form the basis for targeted therapy selection and for molecular characterization efforts such as TCGA...
  47. pmc Double minute chromosomes in glioblastoma multiforme are revealed by precise reconstruction of oncogenic amplicons
    J Zachary Sanborn
    Authors Affiliations Five3 Genomics, LLC Center for Biomolecular Science and Engineering, University of California Howard Hughes Medical Institute, Santa Cruz, California Human Oncology and Pathogenesis Program and Department of Neurosurgery Cytogenetics Laboratory, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York Departments of Neurology and Neurosurgery, Henry Ford Hospital, Detroit, Michigan and Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Cancer Res 73:6036-45. 2013
    ....
  48. doi request reprint Recurrent high-grade glioma: a diagnostic and therapeutic challenge
    Tobias Walbert
    Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI 48202, USA
    Expert Rev Neurother 11:509-18. 2011
    ..Given these advances, it is likely that tailored therapies for tumors harboring specific signaling defects will become more efficient and successful in the management of glioblastoma...
  49. ncbi request reprint A quantitative model of tumor-induced angiogenesis in the nude mouse
    Feng Jiang
    Department of Neurology, Henry Ford Health Sciences Center, Detroit, Michigan, USA
    Neurosurgery 57:320-4. 2005
    ..In this study, we seek to establish such a model in tumor-bearing brain, allowing for a clear demarcation of primary and satellite tumor tissue in conjunction with precise quantification of cerebral microvasculature...
  50. ncbi request reprint The selective Aurora-A kinase inhibitor MLN8237 (alisertib) potently inhibits proliferation of glioblastoma neurosphere tumor stem-like cells and potentiates the effects of temozolomide and ionizing radiation
    Xin Hong
    Department of Neurosurgery, Henry Ford Hospital, Detroit, MI, USA
    Cancer Chemother Pharmacol 73:983-90. 2014
    ..These results further support the potential of Aurora-A inhibitors as primary chemotherapy agents or biologic response modifiers in glioblastoma patients. ..
  51. pmc Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma
    Tracy T Batchelor
    Tracy T Batchelor, Rakesh K Jain, and Gregory Sorensen, Massachusetts General Hospital, Boston, MA Paul Mulholland, University College London, London Rao Gattamaneni, the Christie Foundation Trust Hospital, Manchester, United Kingdom Bart Neyns, Universitair Ziekenhuis Brussel, Brussels, Belgium L Burt Nabors, University of Alabama at Birmingham, Birmingham, AL Mario Campone, Centre Rene Gauducheau, Saint Herblain, France Antje Wick, University of Heidelberg, Heidelberg, Germany Warren Mason, Princess Margaret Hospital, Toronto, Ontario, Canada Tom Mikkelsen, Henry Ford Hospital, Detroit, MI Surasak Phuphanich, Cedars Sinai Medical Center, Los Angeles, CA Lynn S Ashby, Barrow Neurological Institute, Phoenix, AZ John DeGroot, MD Anderson Cancer Center, Houston, TX Lawrence Cher, Austin Health Cancer Services Mark Rosenthal, Royal Melbourne Hospital, Melbourne, 2-1 Hirosawa
    J Clin Oncol 31:3212-8. 2013
    ....
  52. ncbi request reprint Angiogenesis in glioma: molecular mechanisms and roadblocks to translation
    Oliver Bogler
    William and Karen Davidson Laboratory of Brain Tumor Biology, Hermelin Brain Tumor Center, Department of Neurosurgery, Henry Ford Hospital, Detroit, Michigan 48202, USA
    Cancer J 9:205-13. 2003
    ....
  53. pmc The role of emerging and investigational therapies for metastatic brain tumors: a systematic review and evidence-based clinical practice guideline of selected topics
    Jeffrey J Olson
    Department of Neurosurgery, Emory University School of Medicine, Atlanta, GA, USA
    J Neurooncol 96:115-42. 2010
    ..What evidence is available regarding the emerging and investigational therapies for the treatment of metastatic brain tumors?..
  54. doi request reprint Raman spectroscopy to distinguish grey matter, necrosis, and glioblastoma multiforme in frozen tissue sections
    Steven N Kalkanis
    Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI, 48202, USA
    J Neurooncol 116:477-85. 2014
    ..Future work will develop mapped images of diffuse glioma and neoplastic margins toward development of an intraoperative surgical tool...
  55. ncbi request reprint Analysis of glioma cell platinum response by metacomparison of two-dimensional chromatographic proteome profiles
    Christine Billecke
    Hermelin Brain Tumor Center, Department of Neurosurgery, Henry Ford Hospital, Detroit, Michigan 48202, USA
    Mol Cell Proteomics 5:35-42. 2006
    ..As a result, this analysis greatly reduced the list of peaks whose isolation and downstream analysis by mass spectrometry is warranted, accelerating the search for protein markers of response...
  56. pmc Cilengitide-induced temporal variations in transvascular transfer parameters of tumor vasculature in a rat glioma model: identifying potential MRI biomarkers of acute effects
    Tavarekere N Nagaraja
    Department of Anesthesiology, Henry Ford Hospital, Detroit, Michigan, United States of America
    PLoS ONE 8:e84493. 2013
    ..Evaluating acute temporal responses of tumor vasculature to putative anti-angiogenic drugs may help in optimizing their combination with other treatment modalities. ..
  57. pmc A nano-sized PARACEST-fluorescence imaging contrast agent facilitates and validates in vivo CEST MRI detection of glioma
    Meser M Ali
    Henry Ford Hospital, Detroit, MI 48202, USA
    Nanomedicine (Lond) 7:1827-37. 2012
    ..The authors have investigated the usefulness of in vivo chemical exchange saturation transfer MRI for detecting gliomas using a dual-modality imaging contrast agent...
  58. ncbi request reprint Angiogenesis and apoptosis in glioma: two arenas for promising new therapies
    Oliver Bogler
    William and Karen Davidson Laboratory of Brain Tumor Biology, Hermelin Brain Tumor Center, Department of Neurosurgery, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, Michigan 48202, USA
    J Cell Biochem 96:16-24. 2005
    ..In this article we examine some of the issues that have impeded progress, and examine the potential role that integrins may play as targets, with a role in both angiogenesis and apoptosis...
  59. doi request reprint Bevacizumab and irinotecan treatment for progressive diffuse brainstem glioma: case report
    Roy Torcuator
    Department of Neurosurgery, Henry Ford Health System, Hermelin Brain Tumor Center, Detroit, MI, USA
    J Neurooncol 93:409-12. 2009
    ..In this paper, we report our experience in an adult patient with progressive diffuse brainstem glioma treated with bevacizumab and irinotecan...
  60. ncbi request reprint Correlations between magnetic resonance spectroscopy and image-guided histopathology, with special attention to radiation necrosis
    Jack P Rock
    Hermelin Brain Tumor Center, Henry Ford Hospital, Detroit, Michigan 48202, USA
    Neurosurgery 51:912-9; discussion 919-20. 2002
    ..Multivoxel proton magnetic resonance spectroscopic imaging ((1)H MRSI) may be reliable in guiding the clinical management of untreated patients; however, its value in managing previously treated patients remains unclear...
  61. pmc Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme
    Tom Mikkelsen
    Department of Neurology, Henry Ford Health System, Detroit, Michigan 48202, USA
    Invest New Drugs 25:259-63. 2007
    ..This study examined the efficacy, safety and pharmacokinetics of oral CAI in the treatment of patients with newly diagnosed glioblastoma multiforme (GBM) in an open-label, single arm non-randomized phase 2 trial...
  62. pmc Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response
    Nicholas J Szerlip
    Department of Neurosurgery, Wayne State University Medical School, Detroit, MI 48201, USA
    Proc Natl Acad Sci U S A 109:3041-6. 2012
    ..This phenomenon is especially common among tumors with PDGFRA amplification: overall, 43% of PDGFRA-amplified GBM were found to have amplification of EGFR or the hepatocyte growth factor receptor gene (MET) as well...
  63. ncbi request reprint Studying the heterogeneity of brain tumors using medium throughput LOH analysis
    Oliver Bogler
    Hermelin Brain Tumor Center, Department of Neurosurgery, Henry Ford Hospital, Detroit, Michigan 48202, USA
    Cytometry 47:52-5. 2002
  64. doi request reprint Odyssey of hope: a physician's guide to communicating with brain tumor patients across the continuum of care
    Mark L Rosenblum
    Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Hospital, 2799 West Grand Boulevard, Detroit, MI 48202, USA
    J Neurooncol 92:241-51. 2009
    ..We offer suggestions based on our own observations over 17 years as well as the lessons taught to us by our patients and their families over that time and through a structured interview process...
  65. ncbi request reprint Degradation of extracellular matrix protein tenascin-C by cathepsin B: an interaction involved in the progression of gliomas
    Jianxin Mai
    Department of Pharmacology, Wayne State University, School of Medicine, Detroit, MI 48201, USA
    Biol Chem 383:1407-13. 2002
    ..We suggest that interactions between cathepsin B and tenascin-C are involved in the progression of gliomas including the angiogenesis that is a hallmark of anaplastic astrocytomas...
  66. ncbi request reprint Developing a brain tumor center
    Mark L Rosenblum
    Department of Neurosurgery, Hermelin Brain Tumor Center, Henry Ford Health System, Detroit, MI 48202, USA
    J Neurooncol 69:169-80. 2004
    ....
  67. ncbi request reprint SDF-1 and CXCR4 are up-regulated by VEGF and contribute to glioma cell invasion
    Xin Hong
    Department of Neurosurgery, Henry Ford Heath Science Center, Detroit, MI 48202, USA
    Cancer Lett 236:39-45. 2006
    ..VEGF has a direct effect on U251n glioma cell proliferation and invasion. VEGF up-regulates SDF-1 and CXCR4 mRNA expression, and contributes to U251n cell invasion...
  68. ncbi request reprint 2D/3D image fusion for accurate target localization and evaluation of a mask based stereotactic system in fractionated stereotactic radiotherapy of cranial lesions
    Jian Yue Jin
    Department of Radiation Oncology, Henry Ford Hospital, 2799 W Grand Boulevard, Detroit, Michigan 48202, USA
    Med Phys 33:4557-66. 2006
    ..The overall uncertainty of the mask system was +/-4 mm, and the reproducibility was +/-2.9 mm in terms of 95% CI. The study demonstrated that the image guidance system provides accurate and precise target positioning...
  69. pmc Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11
    Tracy T Batchelor
    Brain Tumor Center, Massachusetts General Hospital, Boston, MA 02114, USA
    Neuro Oncol 6:21-7. 2004
    ..Irinotecan had minimal efficacy in this cohort of 18 patients with recurrent malignant glioma. Toxicity was significant but similar to that reported in other patient populations...
  70. ncbi request reprint A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting
    E Antonio Chiocca
    The NABTT CNS Consortium, Baltimore, MD 21231, USA
    Mol Ther 10:958-66. 2004
    ..In 2 patients who underwent a second resection 3 months after ONYX-015 injection, a lymphocytic and plasmacytoid cell infiltrate was observed. Injection of ONYX-015 into glioma cavities is well tolerated at doses up to 10(10) pfu...
  71. ncbi request reprint Assessment of brain tumor angiogenesis inhibitors using perfusion magnetic resonance imaging: quality and analysis results of a phase I trial
    N Shastry Akella
    Department of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, Alabama, USA
    J Magn Reson Imaging 20:913-22. 2004
    ....
  72. ncbi request reprint AMP-dependent protein kinase alpha 2 isoform promotes hypoxia-induced VEGF expression in human glioblastoma
    Kathryn M Neurath
    Department of Cell Biology, Center for Vascular Biology, University of Connecticut Health Center, Farmington, CT 06030 3501, USA
    Glia 53:733-43. 2006
    ....
  73. pmc Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma
    Surasak Phuphanich
    Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Neuro Oncol 10:617-23. 2008
    ..Further study of atrasentan with radiation therapy and temozolomide in newly diagnosed GBM is warranted to evaluate the efficacy of this novel agent...
  74. pmc Altered adenosine-to-inosine RNA editing in human cancer
    Nurit Paz
    Cancer Research Center, Chaim Sheba Medical Center, Tel Hashomer 52621, Israel
    Genome Res 17:1586-95. 2007
    ..Altered epigenetic control was recently shown to play a central role in oncogenesis. We suggest that A-to-I RNA editing may serve as an additional epigenetic mechanism relevant to cancer development and progression...
  75. pmc Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma
    L Burt Nabors
    New Approaches to Brain Tumor Therapy CNS Consortium, Baltimore, MD 21231, USA
    J Clin Oncol 25:1651-7. 2007
    ..This multi-institutional phase I trial was designed to determine the maximum-tolerated dose (MTD) of cilengitide (EMD 121974) and to evaluate the use of perfusion magnetic resonance imaging (MRI) in patients with recurrent malignant glioma...
  76. ncbi request reprint Proteomic comparison of oligodendrogliomas with and without 1pLOH
    Hiroaki Okamoto
    Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke NINDS, National Institutes of Health NIH, Bethesda, Maryland 20892 1414, USA
    Cancer Biol Ther 6:391-6. 2007
    ..Despite a high morphological similarity, tumors with allelic loss on the short arm of chromosome 1 (1pLOH) are more chemosensitive than those without 1pLOH...
  77. doi request reprint Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas
    Aiguo Li
    Neuro Oncology Branch, National Cancer Institute, National Institutes of Neurological Disorder and Stroke, NIH, Bethesda, MD 20892, USA
    Mol Cancer Res 6:21-30. 2008
    ....
  78. ncbi request reprint High-resolution global genomic survey of 178 gliomas reveals novel regions of copy number alteration and allelic imbalances
    Yuri Kotliarov
    Neuro Oncology Branch, National Cancer Institute, Bethesda, MD 20892 4254, USA
    Cancer Res 66:9428-36. 2006
    ..The wealth of genomic data produced may allow for the development of a more rational molecular classification of gliomas and serve as an important starting point in the search for new molecular therapeutic targets...
  79. ncbi request reprint The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochloride
    Stuart A Grossman
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland 21231 1000, and Massachusetts General Hospital, Boston, USA
    Clin Cancer Res 12:5174-81. 2006
    ..This study was conducted to determine if the maximum tolerated dose and pharmacokinetics of PCB are affected by the concurrent use of enzyme-inducing antiseizure drugs (EIASD)...
  80. ncbi request reprint Increased expression of thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10) and survivin is associated with poor survival in glioblastoma multiforme (GBM)
    Jessica M Grunda
    Departments of Pharmacology and Toxicology, Division of Clinical Pharmacology, University of Alabama at Birmingham, Birmingham, AL, 35294, USA
    J Neurooncol 80:261-74. 2006
    ....
  81. ncbi request reprint Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain
    Lixin Sun
    Neuro Oncology Branch, National Cancer Institute National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892, USA
    Cancer Cell 9:287-300. 2006
    ..Thus, the SCF/c-Kit pathway plays an important role in tumor- and normal host cell-induced angiogenesis within the brain...
  82. pmc Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma
    Steven Brem
    Department of Interdisciplinary Oncology and Neurosurgery, University of South Florida College of Medicine and Neuro Oncology Program, H Lee Moffitt Cancer Center, Tampa, FL 33620, USA
    Neuro Oncol 7:246-53. 2005
    ..Although serum copper was effectively reduced by diet and penicillamine, this antiangiogenesis strategy did not improve survival in patients with glioblastoma multiforme...

Research Grants5

  1. INTEGRIN ANTAGONISTS IN GLIOMA BIOLOGY, IMAGING, THERAPY
    Tom Mikkelsen; Fiscal Year: 2003
    ..abstract_text> ..
  2. MOLECULAR GLIOMA THERAPIES AND DIAGNOSTICS
    Tom Mikkelsen; Fiscal Year: 2004
    ..abstract_text> ..
  3. A MULTI-USE GLIOMA BIOREPOSITORY
    Tom Mikkelsen; Fiscal Year: 2006
    ..We seek support to expand this multi-use glioma biorepository into an ongoing resource of the best characterized glioma material with clinical correlative and genomic data available. ..
  4. NEW APPLICATIONS IN BRAIN TUMOR THERAPY
    Tom Mikkelsen; Fiscal Year: 2007
    ..These efforts speak to the ultimate goal of our group and NABTT Consortium: improving the outcome of brain tumor patients. ..